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Peroxisomeproliferation is inducibleinhepatocytesofrodentandnonrodentspeciesbystructurallydissimilar
hypolipidemic drugs and certain phthalate ester plasticizers. The induction of peroxisome proliferation
appears to be a tissue specific response limited largely to the hepatocyte. Peroxisome proliferation is as-
sociated with increases in the activity oftheH202-generating peroxisomal fatty acid 3-oxidation system and
in the amount of peroxisome proliferation-associated 80,000 MW polypeptide (PPA-80). Chronic adminis-
tration ofthese non-DNA damaging and nonmutagenic peroxisome proliferators to rats and mice results in
the development of hepatocellular carcinomas. Comparative morphometric and biochemical data from rats
treated with varying dose levels of ciprofibrate, a hypolipidemic drug, and di(2-ethylhexyl) phthalate, and
di(2-ethylhexyl) adipate, the widely used plasticizers, indicate that the hepatocarcinogenic potency ofthese
agents is correlatable with their ability to induce peroxisome proliferation, peroxisomal 13-oxidation and
PPA-80. Available evidence strongly favors the role ofperoxisome proliferation-associated oxidative stress in
the induction of liver tumors by peroxisome proliferators.
Introduction
The cytoplasmic organelle peroxisome (microbody),
characterized morphologically by a single limiting mem-
brane and a finely granular or homogeneous matrix, is a
ubiquitous structure in animal and plant cells (1-3). In
normal hepatic parenchymal cells, peroxisomes are few
innumberand appear somewhatinsignificant inthe over-
all cytoplasmic organization. Twenty years ago, the hy-
polipidemic agentclofibrate wasthefirstxenobiotic shown
to induce a marked proliferation of peroxisomes in liver
parenchymal cells (4). In recent years, peroxisome pro-
liferationandinductionofperoxisomeassociated enzymes
in the livers ofrodents exposed to a variety of structur-
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allydissimilarhepaticperoxisomeproliferatorshavebeen
extensively studied (5-9). The induction ofperoxisomes
is associated with a severalfold increase in the activity
of the peroxisomal fatty acid P-oxidation system (8,10-
15) and a twofold increase in the activity of catalase
(7,8,16). In addition, long-term exposure to these per-
oxisome proliferators results in the induction ofhepato-
cellular carcinomas in rats and mice (8,17-22). The lack
ofmutagenicity ofthese agents (8, 23-25) combinedwith
consistent coupling of proliferation of H202-generating
peroxisomes led to the hypothesis that persistent prolif-
eration ofperoxisomes serves as an endogenous initiator
of neoplastic transformation by enhancing oxidative
stress (19,26). Since the morphological observation ofhe-
patic peroxisome proliferation is considered a useful
marker of potentially carcinogenic nonmutagenic com-
pounds, we have undertaken a comparative examinationREDDY ET AL.
ofperoxisome proliferative effects ofsome known carcin-
ogenic peroxisome proliferators in order to correlate the
extent of peroxisome proliferation with hepatocarcino-
genicity. Inthisreport, possible mechanisms ofinduction
ofperoxisome proliferation and peroxisome proliferation-
induced liver carcinogenesis are also considered.
Ciprofibrate- and Phthalate Ester-
Induced Peroxisome Proliferation
and Correlation with
Hepatocarcinogenic Potency
Several structurally diverse hypolipidemic agents and
the widely used phthalate ester plasticizers constitute
two major classes of chemicals capable of inducing per-
oxisome proliferation in liver (7,8). Clofibrate and other
hypolipidemic agents are several orders of magnitude
moreeffective ininducinghepatomegaly, peroxisomepro-
liferation, peroxisomeproliferation-associated 80,000mo-
lecular weight polypeptide (PPA-80) and peroxisomal
fatty acid n-oxidation system when compared to phthal-
ate ester plasticizers di(2-ethylhexyl) phthalate (DEHP)
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and di(2-ethylhexyl) adipate (DEHA). For example, clo-
fibrate, when administered at 0.25% dietary level, in-
duces considerable proliferation of peroxisomes in rat
liver (4,5). With DEHP, a level of 2% is necessary to
induce nearly similar levels of peroxisome proliferation
(28,29). A systematic comparison of peroxisome prolif-
erative response and associated enzyme changes in the
livers of rats and mice fed various concentrations of
known carcinogenic peroxisome proliferators such as
DEHP, DEHA, clofibrate, and ciprofibrate is necessary
in order to correlate morphological and biochemical
changes in peroxisomes with the hepatocarcinogenic po-
tency ofthese chemicals. To address this issue, compar-
ative studies wereperformed ingroups ofF344malerats
fed selected dose levels of two plasticizers (DEHP and
DEHA) and a potent hypolipidemic drug (ciprofibrate)
(Fig. 1). In these studies DEHP and DEHA were added
to the diet at 0.25, 0.5, 1, and 2% (wlw) and ciprofibrate
was fed at 0.001, 0.01, and 0.02% (w/w).
After 30 days oftreatment, a dose-dependent increase
in liver weight was noted with ciprofibrate and DEHP
(Fig. 2), whereaswithDEHAtheincreaseinliverweight
was significant atonlythe2%level. Ofparticularinterest
to note is that the increase in liver weight observed in
rats fed ciprofibrate at the 0.01% level was comparable
to that induced by DEHP at the 2% level, suggesting an
approximately 200-fold difference in the hepatomegalic
potency of these two agents in rats. Likewise, the he-
patomegalic effect of ciprofibrate is estimated to be
>1000 times that of DEHA.
A close relationship between hepatomegalic and per-
oxisome proliferative effects of these three agents is
noted (Figs. 3-6). In normal rat liver peroxisomes are
few and randomly distributed (Fig. 3A). Ciprofibrate at
the 0.001% level in the diet caused a perceptible increase
inthe numberofthese organelles (Fig. 3B). Atthis lower
dose level, peroxisomes appeared as focal clusters. At
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FIGURE 1. Chemical structures of: (1) di-(2-ethylhexyl) phthalate; (2)
di(2-ethylhexyl) adipate, and (3) ciprofibrate (2-[4-(2,2-dichlorocy-
clopropyl)phenoxy]2-methylpropionic acid).
FIGURE 2. Changes in liver weight of rats fed diets containing ci-
profibrate, di-(2-ethylhexyl) phthalate (DEHP) or di-(2-ethylhexyl)
adipate (DEHA) for 30 days at the concentrations shown. Bar N
represents normal rats. The values represent mean + SD.
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FIGURE 3. Liver parenchymal cells of(A) normal rat and rats treated with different concentrations ofciprofibrate for 30 days: (B) 0.001%,
(C) 0.01%, and (D) 0.02%. M, mitochondria; P, peroxisomes. OS04; stained with lead citrate. All electron micrographs, approx. x 4650.
0.01% (Fig. 3C) and 0.02% (Fig. 3D), these organelles
were distributed throughout the hepatocyte cytoplasm
and displayed remarkable variation in size. DEHP at the
0.25%dietarylevelcausedaslightincreaseinperoxisome
numberand volumedensity(Fig. 4A). Atthislowerdose,
level peroxisomes were irregular and displayed matrical
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FIGURE 4. Liver parenchymal cells of rats treated with different concentrations of DEHP for 30 days: (A) 0.25%; (B) 0.5%; (C) 1%; (D) 2%.
In rats treated with 0.25% DEHP, some ofthe peroxisomes are slightly irregular in shape and show matrical striations. M,
mitochondria; P, peroxisomes. OSO4; stained with lead citrate. All electron micrographs approximately x 4650.
striations (Fig. 4A). DEHP at higher dose levels caused
a marked increase in peroxisome number (Figs. 4C and
D). The size ofhepaticperoxisomes alsoincreased inrats
fed DEHP at 2% level (Fig. 4C vs. Fig. 4D). DEHA
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FIGURE 5. Liver parenchymal cells ofrats treated with different concentrations of DEHA for 30 days: (A) 0.25%; (B) 0.5%; (C) 1%; (D)
2%. P, peroxisomes. 0804; stained with lead citrate. Al electron micrographs approximately x 4650.
exerted no perceptible effect on peroxisome number at
0.25% and 0.5% dose levels (Figs. 5A and B), but at the
1% and 2% levels, the peroxisome proliferation was evi-
dent (Figs. 5C and D). However, even at the 2% dietary
level, DEHA induced only a moderate degree of perox-
isome proliferation in rat liver cells. Quantitative mor-
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FIGURE 6. Changes inperoxisome volume densityin liverparenchymal
cells ofratsfeddietscontainingciprofibrate, di(2-ethylhexyl) phthal-
ate (DEHP) or di(2-ethylhexyl) adipate (DEHA) for 30 days at the
concentrations shown. Bar N represents normal rats. The values
are mean + SD.
phometric changes in peroxisome volume density pre-
sentedinFigure 6confirmthe qualitative ultrastructural
observations.
Several studies have clearly established that the in-
duction of peroxisome proliferation is associated with a
significant increase in the activities of the peroxisomal
marker exzyme catalase and the peroxisomal fatty acid
p-oxidation system (8). Table 1 presents the results of
changes in catalase and peroxisomal '4C-palmitoyl-CoA
oxidation in the livers of rats treated with varying con-
centrations of DEHP, DEHA, or ciprofibrate. Changes
in the fatty acid a-oxidation system appeared to parallel
the alterations in peroxisome volume density. As ex-
pected, the increase in specific activity of catalase was
about 2-fold at the maximum level of peroxisome prolif-
eration (Table 1).
The xenobiotic-induced increase in peroxisome popu-
lation is associated with specific changes in the compo-
sition ofhepatocyte proteins (30). Of particular interest
is the remarkable increase in the content of PPA-80
(27,30), which has been identified as the bifunctional pro-
teinofthe peroxisomalfattyacid p-oxidation system (31).
To further evaluate the relative potency of DEHP,
DEHA, and ciprofibrate as peroxisome proliferators,
post-nuclear fractions of liver were analyzed by SDS-
polyacrylamide gel electrophoresis (Fig. 7). A dose-de-
pendent increase in the amount of PPA-80 was clearly
evident with ciprofibrate, DEHP, and DEHA. Further-
more, these data also demonstrate that ciprofibrate is
more potentthanDEHPininducingPPA-80. Ofthethree
agents, DEHA is the weakest inducer ofPPA-80 even at
the 2% dietary level. Figures 8 and 9 present repre-
sentative densitometric tracings. As shown in Figure 9,
DEHP at the 2% dietary level appeared to induce more
than twice as much of an increase in PPA-80 content as
did DEHA administered at the same dose level. Immu-
noblot analysiswithantiPPA-80antibodies confirmedthe
dose-dependent increases in the amounts ofPPA-80 (Fig.
10B), whereas immunoblots with anticatalase antiserum
showed only subtle changes in the amounts of catalase
(Fig. 10A).
These observations clearly indicate that ciprofibrate,
at 0.02 and 0.01% dietary concentrations, induces re-
markable increases in the peroxisome population and
PPA-80 contentinratliver. This compound inducesnearly
a 100% incidence of liver tumors in rats when adminis-
tered at 10mg/kgbodyweight(i.e., 0.02-0.025% dietary
level) for 60 weeks (32). Unpublished observations show
thatthis compoundisalsohepatocarcinogenic whengiven
at 5 mg/kg dose level (i.e., at 0.01% dietary level). It
is also pertinent to point out that DEHP at 0.6 and 1.2%
dietary level induced hepatocellular neoplasms in only
about 10-15% of the rats (21). The difference in tumor
incidence appears to correlate well with the degree of
induction of peroxisome proliferation (see Fig. 4) and
PPA-80 at these dose levels. The relatively low incidence
of tumors in rats and mice fed DEHA similarly reflects
the relatively weakperoxisome proliferative effect ofthis
agent observed at the 2% dietary level (see Fig. 5).
Table 1. Changes in liver catalase and peroxisomal ,3-oxidation.
[1-14C]-palmitoyl-CoA oxidation,
Group Dose, % in dieta Catalase, units/mgproteinb ±tmole/min/g liverb
Normal 42 ± 3 1.1 ± 0.01
Ciprofibrate 0.001 52 ± 2 5.8 ± 2.5
0.01 76±3 12.9±0.5
0.02 98±3 14.6±0.2
DEHP 0.25 48 ± 3 4.4 ± 0.1
0.50 55±2 6.1±0.3
1.0 58±3 5.9±0.9
2.0 70 ± 3 10.7 ± 1.0
DEHA 0.25 46 ± 3 2.9 ± 0.9
0.50 49±2 2.8±0.1
1.0 57±4 3.7±0.1
2.0 63±3 6.8±0.4
aThe compound was mixed in the powdered rat chow at the level (% w/w) indicated. Male F344 rats were maintained on these diets for 30
days before sacrifice.
bThe values are mean ± SD of 3 to 4 animals in each group.
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FIGURE 7. Relative potency of two plasticizers and ciprofibrate to induce peroxisome proliferation associated polypeptide (PPA-80). SDS-poly-
acrylamide slab gel electrophoretic patterns ofpost-nuclear fractions ofliver ofnormal rat (N), and rats fed diets containing ciprofibrate: (lane
1) 0.001%; (lane 2) 0.01%; (lane 3) 0.02% in diet; di-(2-ethylhexyl) phthalate: (lane 4) 0.25%, (lane 5) 0.5%, (lane 6) 1.0%, (lane 7) 2.0% in diet;
and di-(2-ethylhexyl) adipate: (lane 8) 0.25%, (lane 9) 0.5%, (lane 10) 1.0%, (lane 11) 2.0% in diet for 30 days. The arrows indicate the position
of the peroxisome proliferation associated 80,000 molecular weight polypeptide, which represents the bifunctional (enoyl-CoA hydratase-
dehydrogenase) enzyme ofthe peroxisomal fatty acid ,-oxidation enzyme system. Approximately 30 ,ug protein was loaded in each slot.
Tissue Specificity in the Induction
of Peroxisome Proliferation
Peroxisomes are present in all cell types (3). They ap-
pear prominent in hepatic parenchymal cells and in prox-
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FIGURE 8. Densitometric scans of one-dimensional SDS-polyacrylam-
ide slab gel electrophoretic patterns of post-nuclear fractions ob-
tained from the livers of (A) normal and (B) ciprofibrate-treated
(0.001% w/w in diet) rats. The vertical arrow indicates the position
of peroxisome proliferation associated polypeptide (- molecular
weight 80,000), which is the bifunctional enzyme ofthe peroxisomal
fatty acid p-oxidation system. Approximately 30 ,ug protein was
loaded in each slot.
imal convoluted tubular epithelium of kidney (1). These
organelles in nonhepatic cells are sometimes referred to
as microperoxisomes because of their small size (33).
Available evidenceindicatesthatperoxisome proliferators
exert their peroxisome proliferative and PPA-80 inducing
effects mostly in liver parenchymal cells and to a lesser
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FIGURE 9. Densitometric scans ofone-dimensional SDS-polyacrylam-
ide slab gel electrophoretic patterns of post-nuclear fractions ob-
tained from the livers of(A) di(2-ethylhexyl) phthalate-treated (2%
w/w in diet) and (B) di(2-ethylhexyl) adipate-treated (2% w/w in
diet) rats. The vertical arrow indicates the position of peroxisome
proliferation associated polypeptide. See Fig. 8 for patterns of nor-
malandciprofibrate-treated rat livers. Approximately30 ,ugprotein
was loaded in each slot.
B
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FIGURE 10. Immunoblotting of electrophoretically separated polypeptides of postnuclear fractions of liver of normal rats (N) and rats fed diets
containingdifferentconcentrationsofciprofibrate (lanes 1-3), di(-2-ethylhexyl) phthalate (DEHP)(lanes4-7) ordi(2-ethylhexyl)adipate (DEHA)
(lanes 8-11). For dose levels see legend for Fig. 7. Electrophoretically separated (- 10 ,ug per lane in panel B and - 50 ,ug per lane in panel
A)proteinsweretransferred tonitrocellulose andimmunoblotted withantiserumforratcatalase (A), orwithperoxisomeproliferationassociated
80,000 molecular weight polypeptide (B). The immune complexes were detected by autoradiography following treatment with 125I-labeled
protein. In panelA, the intensity ofcatalase ofbands in treated animals is slightly increased when compared to that ofnormal (N). In general,
the maximum increase in catalase protein is about two-fold. In Panel B peroxisome proliferation associated 80,000 molecular weight protein
(bifunctional protein ofperoxisomal ,-oxidation) is barely detectable in normal post-nuclear fractions. This protein is induced in a dose related
fashion in treated rats. The relative potency ofthe three peroxisome proliferators can be assessed by comparing the intensity ofthe bands in
lane 2 (ciprofibrate 0.01%) with lane 6 (DEHP 2%) and lane 1 (ciprofibrate 0.001%) with lane 10 (DEHA 1%). This suggests that ciprofibrate
is at least 200 times more potent than DEHP and 1000 times more potent than DEHA.
extent in the proximal tubular epithelium of the kidney
(8,11). Although slight increases in the activities of cat-
alase, fatty acyl-CoA oxidase, and/or the peroxisomal
fatty acid ,-oxidation enzyme system were reported in
certain nonhepatic tissues, includingsmallintestinal mu-
cosa, following treatment with clofibrate or other per-
oxisome proliferators (34,35), recent ultrastructural
studies as well as high-resolution two-dimensional analy-
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sis ofproteins of small intestine, heart, skeletal muscle,
testis, adrenal, brain, and lung of rats fed ciprofibrate,
a potent carcinogenic hepatic peroxisome proliferator,
failed to demonstrate peroxisome proliferation and in-
duction ofPPA-80 inthese nonhepatic tissues (36). These
results clearly show that ciprofibrate-induced-and by
implication other peroxisome proliferator-induced-per-
oxisomal gene expression is largely liver specific.
Peroxisome proliferation was also inducible by ci-
profibrate and DEHP, in hepatocytes transplanted in in-
terscapular fat pads (37) or in the anterior chamber of
the eye (38). The magnitude of increase in peroxisome
volume density in transplanted hepatocytes at these ex-
trahepatic sites was comparable to the increase in the
volume density ofthese organelles in the homotopic liver
cells (37). The absence of peroxisome proliferation in
brown fat cells or epithelial cells of the eye, which are
adjacent to hepatocytes at these transplantation sites,
further supports the contention that peroxisome prolif-
erative response is a hepatocyte specific phenomenon.
Another piece ofevidence in favor oftissue specificity in
the induction ofperoxisome proliferation comes from the
observation of peroxisome proliferation in transdiffer-
entiated hepatocytes in rat and hamster pancreas
(39,40). In these studies, drug-induced peroxisome pro-
liferation was observed in pancreatic hepatocytes, but
not in adjacent pancreatic acinar and endocrine cells
(39,40). Therefore, it is reasonable to conclude that he-
patocytes, irrespective oftheir location in the body, re-
cognize peroxisome proliferators and respond to their
stimulating effect on peroxisome-specific gene expres-
sion.
Mechanism of Peroxisome
Proliferation
Tissue-specific biological response resulting from the
administration ofstructurally dissimilarperoxisome pro-
liferators suggests that the interaction of these agents
with a receptor(s) might be the mechanism responsible
for peroxisome proliferation. Lalwani et al. (41) have de-
scribed specific binding of [3H]-nafenopin, a peroxisome
proliferator, to liver cytosol. The presence ofsuch a bind-
ingprotein(s) inhepatocytes (41) and its relative absence
in other tissues can account for the difference in tissue
inducibility ofperoxisomes. The induction ofperoxisome
proliferation in primary liver cell cultures by these per-
oxisome proliferators under serum free conditions pro-
vides further support for the peroxisome proliferator-
receptor interaction (42). Physichcochemical character-
ization of peroxisome proliferator specific receptor(s) is
essential for elucidation ofthe biochemical mechanism by
which a peroxisome proliferator-receptor complex acti-
vates specific genes.
Hypolipidemic peroxisome proliferators such as clofi-
brate, ciprofibrate, andmethylclofenapatedonotrequire
extensive metabolic transformation. Compounds which
are in the form ofethyl or methyl esters (i.e., clofibrate
and methyl clofenapate) are converted into free acids and
usually excreted as glucuronide conjugates. Compounds
which are in the acid form (i.e., ciprofibrate and nafen-
opin) are present in the circulation as such and are ex-
creted as glucuronide conjugates. The receptor-binding
moiety, therefore, appears to be the acid form of these
hypolipidemic agents. The plasticizer DEHP undergoes
extensive metabolic conversion (43), and it is not certain
whether the metabolite monoethylhexyl phthalate or the
metabolite 2-ethylhexanol is the moiety capable of in-
ducing peroxisome proliferation (29).
Mechanism of Peroxisome
Proliferator-Induced Liver
Carcinogenesis
Reddy et al. (19) proposed that hepatic peroxisome
proliferators constitute a novel class of chemical carcin-
ogens. Several studies have now established that com-
pounds capable of inducing peroxisome proliferation are
hepatocarcinogenic in both mice and rats when admin-
istered chronically in the diet (8). None ofthese carcin-
ogenic peroxisome proliferators has been shown to be
mutagenic in bacterial assays (20,23-25,44). Further-
more, no carcinogenic peroxisome proliferators, including
hypolipidemic drugs and phthalate ester plasticizers dis-
played any capacity to covalently modify or damage cel-
lular DNA either in vivo or tn vitro (23,24,44-48). Re-
cently, we examined, using the 32P-postlabeling assay,
the ability of clofibrate, ciprofibrate, Wy-14,643, and
DEHP to form DNA adducts in liver (49). With this
highly sensitive method, which is capable of detecting
one adduct in 109-101 normal nucleotides, we found no
peroxisome proliferator-DNA adducts (49). It is, there-
fore, reasonable to conclude that, with peroxisome pro-
liferators, formation of a DNA adduct may not be a nec-
essary step for carcinogenesis.
As discussed elsewhere (8,19,26), the carcinogenicity
ofthese nonmutagenic and non-DNA adduct-formingper-
oxisomeproliferators appears toberelatedtobiologically
active products of the proliferated peroxisomes rather
than a direct chemical effect. Evidence supporting the
roleofperoxisome proliferationmediatedoxidative stress
as a possible hepatocarcinogenic mechanism includes: (a)
consistent association between the induction of peroxi-
some proliferation andhepatocellularcarcinomas (17-21);
(b) sustained and specific induction of H202-generating
peroxisomal fatty acid ,-oxidation system and PPA-80
(8,11-15); (C) increased intracellular levels ofH202 in liv-
erswithperoxisomeproliferation(15,50,51); (d)increased
accumulation of lipofuscin in livers following chronic in-
duction of peroxisome proliferation (26); (e) marked in-
hibition of peroxisome proliferator-induced carcinogen-
esis by antioxidants ethoxyquin and butylated
hydroxyanisole (32); and (f) DNA damaging capability of
hypolipidemic drug induced liver peroxisomes (50). In
addition, the recent identification of an oxidase in per-
oxisomal membrane capable of oxidizing glycerol phos-
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phate, xanthine, or aldehydes (52) further supports the
mechanism of peroxisome proliferation associated oxi-
dative stress. This peroxisomal membrane oxidase is
capable of generating O2 and H202, and, as pointed
out recently, the increased generation ofH202 and 02
by proliferated peroxisomes may lead to OH' (hydroxy
radical) formation (50). Although these reactive oxygen
species are known to interact with cellular macromole-
cules including DNA, considerable work is needed to
identify the mechanism by which these oxygen radicals
cause liver cancer. Whether oxidative stress resulting
from sustained proliferation of peroxisomes leads to
DNA damage oralters the expression ofoncogenes and
growth factors is not known.
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